title: [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
abstract: OBJECTIVE
  The BRAF(T1799A) mutation is reported to be associated to aggressive, persistent, and recurrent tumor in papillary thyroid carcinoma (PTC) patients. Association of the BRAF(T1799A) mutation in the primary tumor with the clinicopathological characteristics of PTC patients was analyzed.
  
  
  METHODS
  Ninety-seven PTC patients were followed up for a median of 64.1 months. The BRAF(T1799A) mutation was analyzed in DNA from initial thyroidectomy biopsies by PCR amplification and restriction fragment length polymorphism using TspRI enzyme. Positive cases were confirmed by DNA sequencing. Statistical association between BRAF(T1799A) mutation and clinicopathological characteristics was analyzed by the relevant hypothesis tests and logistic regression.
  
  
  RESULTS
  46.4% of patients were positive for the BRAF(T1799A) mutation. Bivariate and multivariate analysis showed the BRAF(T1799A) mutation to be only associated to age over 60years (odds ratio [OR] = 5.5; 95% confidence interval [CI],1.4-21.9; p=0.019) and to tumor size of 1cm or greater (OR=3.6, 95% CI, 1.2-10.3; p=0.016). The BRAF(T1799A) mutation was not associated to histological subtype, metastasis, recurrence, more aggressive treatments (ablative I(131) therapy or surgery), or PTC persistence at the end of follow-up.
  
  
  CONCLUSIONS
  The BRAFT1799A mutation is associated to age over 60 and a tumor size of 1cm or greater, but not to other clinicopathological characteristics, tumor recurrence or PTC persistence.
authors: Servicio de Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Granada. marisacgarre@gmail.com
authors: Marisa
authors: M
authors: Cañadas Garre
authors: Martín
authors: M
authors: López de la Torre Casares
authors: Patricia
authors: P
authors: Becerra Massare
authors: Miguel Ángel
authors: MÁ
authors: López Nevot
authors: Jesús
authors: J
authors: Villar Del Moral
authors: Nuria
authors: N
authors: Muñoz Pérez
authors: Ricardo
authors: R
authors: Vílchez Joya
authors: Rosa
authors: R
authors: Montes Ramírez
authors: José Manuel
authors: JM
authors: Llamas Elvira
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D019943:Amino Acid Substitution; D014408:Biomarkers, Tumor / Q000235:genetics*; D002291:Carcinoma, Papillary / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D004273:DNA, Neoplasm / Q000235:genetics; D005091:Exons / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000235:genetics*; D017354:Point Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012008:Recurrence; D012189:Retrospective Studies; D012306:Risk; D013964:Thyroid Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D013965:Thyroidectomy; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D007457:Iodine Radioisotopes; D009363:Neoplasm Proteins; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf